CXCR4 and neoplasm: In the other subgroup of 22 IGHV mutated cases, with a stronger BCR/CXCR4 downregulation profile, a majority (64%) had tumor progression with lymphadenopathy, and 7 of them required treatment for nodal progression with a median follow up of 9.2 years.